Dr. Gary Novack attended the biennial Glaucoma Research Society meeting in Cambridge, where researchers discussed innovative glaucoma research and the development of novel therapies.
Dr. Gary Novack was recently quoted in The New York Times and featured by UC Davis Health for his expert perspective on a nationwide recall of prescription eye drops.
Dr. Novack presented multiple sessions at Napa Eye 2026, including research on novel ophthalmic medications and a lecture on FDA marketing authorization for ophthalmic drugs and devices.
Dr. Gary Novack attended the 2026 ARVO Annual Meeting in Denver, continuing a tradition of more than 40 years participating in one of ophthalmology’s leading scientific conferences. During the meeting, he presented research on FDA review times and a novel investigational treatment for pterygia while connecting with colleagues and collaborators in vision science.
Dr. Gary Novack presented Grand Rounds at the University of Louisville, discussing the translation of ophthalmic research into real-world therapies.
Dr. Novack attended the American Glaucoma Society Annual Meeting in Rancho Mirage, CA to explore the latest advances in glaucoma diagnosis, therapy, and research alongside leading experts in the field.
Dr. Novack participated in the Glaucoma Research Foundation’s January 2026 New Horizons Forum, a collaborative gathering focused on emerging glaucoma therapies, diagnostics, and patient-driven innovation.
At the 2026 JPMorgan Healthcare Conference in San Francisco, Dr. Novack met with biomedical companies to advise PharmaLogic clients on regulatory and development issues affecting investigational ophthalmic therapeutics, amid renewed optimism across the life sciences industry.
Singapore, November 2025 — Dr. Novack delivered a lecture on ophthalmic drug development at the Singapore National Eye Centre (SNEC) and Singapore Eye Research Institute (SERI)…
Ann Arbor, November 2025 — Dr. Novack attended the Mary Tyler Moore Vision Initiative Annual Meeting, collaborating with leaders in ophthalmology and vision science to reduce diabetic vision loss…
Research Milestone, July 2025 — Dr. Novack published his 400th scientific paper, marking a significant contribution to ophthalmology and vision science research…
Durham, November 2024 — Dr. Novack presented at Duke University Eye Center, sharing insights from his work in ophthalmology and drug development…
Chicago, October 2024 — Dr. Novack attended the American Academy of Ophthalmology Annual Meeting, reconnecting with colleagues and engaging with the latest advances in eye care…
Public Education, August 2024 — Dr. Novack’s work on the safe use of over-the-counter ocular medications was highlighted through academic and professional outreach…
Regulatory Affairs, June 2024 — Dr. Novack authored the lead article on FDA regulation of ophthalmic drugs in the American Journal of Ophthalmology…
Media Coverage, April 2024 — Dr. Novack was cited in a New York Times article discussing the safety of ophthalmic medications…
Editorial Leadership, April 2024 — Dr. Novack’s ongoing contributions to the Journal of Ocular Pharmacology and Therapeutics highlight his leadership in the field…
Podcast Feature, September 2023 — Dr. Novack joined a podcast discussion focused on emerging glaucoma therapies and drug development…
Professional Recognition, June 2023 — Dr. Novack was selected as a Fellow of the Association for Ocular Pharmacology and Therapeutics (AOPT)…
Ann Arbor, June 2023 — Dr. Novack delivered a lecture at the University of Michigan on advancements in ophthalmic research and therapeutics…
New Orleans, May 2023 — Dr. Novack attended the ARVO Annual Meeting, engaging in scientific exchange and collaboration with vision researchers…
Clinical Research, November 2022 — Dr. Novack co-authored a publication on low-concentration atropine for myopia control…
Professional Honor, September 2022 — Dr. Novack was honored by the American Academy of Ophthalmology for his contributions to the field…
Scientific Presentation, September 2022 — Dr. Novack presented research and perspectives on emerging glaucoma drug therapies…
Napa, May 2022 — Dr. Novack presented at the UC Davis Ophthalmology Course, contributing to continuing medical education programming…
Academic Service, June 2022 — Dr. Novack served as a judge for ophthalmology research presentations at UC Davis…
Media Feature, May 2022 — Dr. Novack was featured in The Ophthalmologist, highlighting his impact on ophthalmic drug development…
Denver, May 2022 — Dr. Novack presented research posters at the ARVO Annual Meeting, contributing to preclinical and clinical discussions…
With a recent product approval, Dr. Novack has now made substantial contributions to 60 approved products during his career…
PharmaLogic Development, Inc. has been contracted to provide service to Zhaoke Ophthalmology Limited in their ophthalmic product development…
In a recent article in JAMA Oncology on the use of surrogate endpoints in oncology, del Paggio et al identified industry funding for nearly all. They further highlighted the use of medical writers in papers published on this work to be of concern…
Glaukos announced that 200 papers published on their glaucoma product, the iStent. . We’re pleased to say that Dr. Novack was the medical writer for lead authors Dr. Thomas Samuelson and L. Jay Katz on the first one, in Ophthalmology…
The American Glaucoma Society recently sought to identify 100 articles with significant impact on the clinical care of patients with glaucoma. This was based upon citation frequency and the input of members of the Society…
The American Academy of Ophthalmology reported (June 2021) a shortage of bevacizumab as used off-label, aliquoted, for ophthalmic indications in the U.S. The issue surrounding off-label and compounding pharmacy use, particularly with this class of products, were discussed in a recent editorial by Dr. Novack…
Together with UC Davis Ophthalmology faculty member, Ala Moshiri, M.D., Ph.D., I published a commentary in the American Journal of Ophthalmology regarding the challenges to making off-label use of products a standard of care in retina therapies in ophthalmology…
The American Academy of Ophthalmology recently updated its Glaucoma Practice Pattern. In this document, also published in the AAO’s Journal Ophthalmology, the Committee, headed by Steven J. Gedde, M.D., glaucoma is defined as a chronic, progressive optic neuropathy…
Gary Novack was honored by the UC Santa Cruz Foundation, an organization of which he is a past president. Together with past Executive Director Ann McCrow and past president Gordon Ringold, ten year ago he helped to execute the Board Opportunity Fund…
My article with Michele Lim MD is listed first in the American Journal of Ophthalmology, December 2019 issue. This was my personal patient’s view of retinal detachment, including my atypical presentation of symptoms…